The Future of Front-line Metastatic Bladder Cancer is Platinum-free

Matthew Young

doi:10.1016/j.euf.2024.04.005

The Future of Front-line Metastatic Bladder Cancer is Platinum-free

Eur Urol Focus. 2024 Apr 23:S2405-4569(24)00057-9. doi: 10.1016/j.euf.2024.04.005. Online ahead of print.

Author

Matthew Young¹

Affiliation

¹ Barts Cancer Institute, Queen Mary University of London, London, UK. Electronic address: m.young21@nhs.net.

PMID: 38658299
DOI: 10.1016/j.euf.2024.04.005

Abstract

Management of metastatic bladder cancer has historically been challenging. However, enfortumab vedotin plus pembrolizumab (EV/P) has recently been accepted as a new standard of care, replacing platinum-based chemotherapy, because of improvements in survival and response rates. The benefits of the EV/P combination and some of the questions that arise in this new treatment landscape are discussed.